EE05537B1 - Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks - Google Patents
Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseksInfo
- Publication number
- EE05537B1 EE05537B1 EEP200300355A EEP200300355A EE05537B1 EE 05537 B1 EE05537 B1 EE 05537B1 EE P200300355 A EEP200300355 A EE P200300355A EE P200300355 A EEP200300355 A EE P200300355A EE 05537 B1 EE05537 B1 EE 05537B1
- Authority
- EE
- Estonia
- Prior art keywords
- neublastin
- methods
- polymeric conjugates
- conjugates
- polymeric
- Prior art date
Links
- 102100026376 Artemin Human genes 0.000 title 1
- 101000785776 Homo sapiens Artemin Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26607101P | 2001-02-01 | 2001-02-01 | |
| PCT/US2002/002319 WO2002060929A2 (en) | 2001-02-01 | 2002-01-25 | Polymer conjugates of neublastin and methods of using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EE200300355A EE200300355A (et) | 2003-10-15 |
| EE05537B1 true EE05537B1 (et) | 2012-04-16 |
Family
ID=23013042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200300355A EE05537B1 (et) | 2001-02-01 | 2002-01-25 | Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks |
Country Status (36)
| Country | Link |
|---|---|
| EP (2) | EP1862475A1 (xx) |
| JP (2) | JP4259868B2 (xx) |
| KR (2) | KR100960063B1 (xx) |
| CN (1) | CN1500095B (xx) |
| AR (1) | AR035077A1 (xx) |
| AT (1) | ATE365748T1 (xx) |
| AU (1) | AU2002247037B2 (xx) |
| BG (1) | BG66393B1 (xx) |
| BR (1) | BR0206852A (xx) |
| CA (1) | CA2436407C (xx) |
| CY (1) | CY1106886T1 (xx) |
| CZ (1) | CZ20032080A3 (xx) |
| DE (1) | DE60220879T2 (xx) |
| DK (1) | DK1355936T3 (xx) |
| EA (1) | EA009771B1 (xx) |
| EE (1) | EE05537B1 (xx) |
| ES (1) | ES2289091T3 (xx) |
| GE (1) | GEP20063916B (xx) |
| HK (1) | HK1057759A1 (xx) |
| HU (1) | HU228973B1 (xx) |
| IL (2) | IL156941A0 (xx) |
| IS (1) | IS2867B (xx) |
| MX (1) | MXPA03006805A (xx) |
| MY (1) | MY143685A (xx) |
| NO (1) | NO332150B1 (xx) |
| NZ (1) | NZ527863A (xx) |
| PL (1) | PL211162B1 (xx) |
| PT (1) | PT1355936E (xx) |
| RS (1) | RS50857B (xx) |
| SG (1) | SG149685A1 (xx) |
| SI (1) | SI1355936T1 (xx) |
| SK (1) | SK288123B6 (xx) |
| TR (1) | TR200301208T2 (xx) |
| UA (2) | UA100967C2 (xx) |
| WO (1) | WO2002060929A2 (xx) |
| ZA (1) | ZA200305733B (xx) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442370B2 (en) | 2001-02-01 | 2008-10-28 | Biogen Idec Ma Inc. | Polymer conjugates of mutated neublastin |
| WO2002060929A2 (en) * | 2001-02-01 | 2002-08-08 | Biogen, Inc. | Polymer conjugates of neublastin and methods of using same |
| US7276580B2 (en) | 2001-03-12 | 2007-10-02 | Biogen Idec Ma Inc. | Neurotrophic factors |
| EP1395279B1 (en) * | 2001-03-28 | 2011-10-05 | Biogen Idec MA Inc. | Use of neublastin polypeptides for treating neuropathic pain |
| HUE028163T2 (en) * | 2002-01-18 | 2016-11-28 | Biogen Ma Inc | Polyalkylene polymer compounds and their use |
| EA008743B1 (ru) * | 2003-01-31 | 2007-08-31 | Байоджен Айдек Ма Инк. | Полимерные конъюгаты мутантного неубластина |
| NZ574121A (en) | 2003-04-18 | 2011-06-30 | Biogen Idec Inc | Polyethylene glycol-conjugated gylcosylated neublastin and uses thereof for treatment of pain |
| BRPI0411243A (pt) | 2003-06-10 | 2006-07-11 | Nsgene As | método de produzir um polipeptìdio de neublastina biologicamente ativo, ácido nucléico, vetor de expressão, composição farmacêutica, célula, linha de células de compactação, mamìfero não-humano transgênico, dispositivo de cultura de células implantável, uso do vetor, método de tratar uma doença do sistema nervoso, e, polipetìdio de neublastina |
| US7598059B2 (en) | 2003-10-02 | 2009-10-06 | Biogen Idec Ma Inc. | Neublastin expression constructs |
| NZ553431A (en) | 2004-08-19 | 2010-04-30 | Biogen Idec Inc | Neublastin variants with decreased heparin binding |
| CA2577690C (en) * | 2004-08-19 | 2013-08-06 | Biogen Idec Ma Inc. | Refolding transforming growth factor beta family proteins |
| TWI501774B (zh) | 2006-02-27 | 2015-10-01 | Biogen Idec Inc | 神經性病症之治療 |
| US20100056440A1 (en) * | 2006-03-01 | 2010-03-04 | Biogen Idec Ma Inc. | Compositions and methods for administering gdnf ligand family proteins |
| JP2010503630A (ja) | 2006-09-15 | 2010-02-04 | クレアビリス・セラピューティクス・エスピーエー | ＨＭＧＢ１のＢｏｘ−ＡおよびＨＭＧＢ１のＢｏｘ−Ａ変異体のポリマー複合体 |
| EP2142205B1 (en) * | 2007-05-01 | 2014-04-02 | Biogen Idec MA Inc. | Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow |
| PL2773438T5 (pl) * | 2011-11-02 | 2022-01-17 | F.Hoffmann-La Roche Ag | Chromatografia przeciążenia i elucji |
| RU2488635C1 (ru) * | 2012-03-22 | 2013-07-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития | Способ получения рекомбинантного антиангиогенного полипептида |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6472178B1 (en) * | 1998-02-27 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding a modified ciliary neurotrophic factor and method of making thereof |
| US5770577A (en) * | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
| US6593133B1 (en) * | 1998-07-06 | 2003-07-15 | Nsgene A/S | Neurotrophic factors |
| AU2354600A (en) * | 1998-12-09 | 2000-06-26 | Amgen, Inc. | Grnf4 a neurotrophic factor |
| WO2002060929A2 (en) * | 2001-02-01 | 2002-08-08 | Biogen, Inc. | Polymer conjugates of neublastin and methods of using same |
-
2002
- 2002-01-25 WO PCT/US2002/002319 patent/WO2002060929A2/en active IP Right Grant
- 2002-01-25 EA EA200300852A patent/EA009771B1/ru not_active IP Right Cessation
- 2002-01-25 CN CN028077539A patent/CN1500095B/zh not_active Expired - Fee Related
- 2002-01-25 AT AT02714792T patent/ATE365748T1/de active
- 2002-01-25 MX MXPA03006805A patent/MXPA03006805A/es active IP Right Grant
- 2002-01-25 UA UAA200802148A patent/UA100967C2/ru unknown
- 2002-01-25 EE EEP200300355A patent/EE05537B1/xx not_active IP Right Cessation
- 2002-01-25 AR ARP020100279A patent/AR035077A1/es not_active Application Discontinuation
- 2002-01-25 SK SK971-2003A patent/SK288123B6/sk not_active IP Right Cessation
- 2002-01-25 CA CA2436407A patent/CA2436407C/en not_active Expired - Fee Related
- 2002-01-25 PL PL372101A patent/PL211162B1/pl unknown
- 2002-01-25 SI SI200230580T patent/SI1355936T1/sl unknown
- 2002-01-25 SG SG200504719-6A patent/SG149685A1/en unknown
- 2002-01-25 EP EP07110666A patent/EP1862475A1/en not_active Withdrawn
- 2002-01-25 IL IL15694102A patent/IL156941A0/xx unknown
- 2002-01-25 GE GE5240A patent/GEP20063916B/en unknown
- 2002-01-25 EP EP02714792A patent/EP1355936B1/en not_active Expired - Lifetime
- 2002-01-25 DE DE60220879T patent/DE60220879T2/de not_active Expired - Lifetime
- 2002-01-25 NZ NZ527863A patent/NZ527863A/en not_active IP Right Cessation
- 2002-01-25 RS YUP-610/03A patent/RS50857B/sr unknown
- 2002-01-25 UA UA2003088104A patent/UA82983C2/ru unknown
- 2002-01-25 DK DK02714792T patent/DK1355936T3/da active
- 2002-01-25 ES ES02714792T patent/ES2289091T3/es not_active Expired - Lifetime
- 2002-01-25 HU HU0500637A patent/HU228973B1/hu not_active IP Right Cessation
- 2002-01-25 KR KR1020087022638A patent/KR100960063B1/ko not_active IP Right Cessation
- 2002-01-25 CZ CZ20032080A patent/CZ20032080A3/cs unknown
- 2002-01-25 PT PT02714792T patent/PT1355936E/pt unknown
- 2002-01-25 KR KR1020037010127A patent/KR100872807B1/ko not_active IP Right Cessation
- 2002-01-25 JP JP2002561497A patent/JP4259868B2/ja not_active Expired - Fee Related
- 2002-01-25 BR BR0206852-4A patent/BR0206852A/pt not_active Application Discontinuation
- 2002-01-25 TR TR2003/01208T patent/TR200301208T2/xx unknown
- 2002-01-25 AU AU2002247037A patent/AU2002247037B2/en not_active Ceased
- 2002-02-04 MY MYPI20020368A patent/MY143685A/en unknown
-
2003
- 2003-07-15 IL IL156941A patent/IL156941A/en not_active IP Right Cessation
- 2003-07-17 IS IS6879A patent/IS2867B/is unknown
- 2003-07-24 ZA ZA2003/05733A patent/ZA200305733B/en unknown
- 2003-08-01 NO NO20033441A patent/NO332150B1/no not_active IP Right Cessation
- 2003-08-19 BG BG108111A patent/BG66393B1/bg unknown
- 2003-11-21 HK HK03108539A patent/HK1057759A1/xx not_active IP Right Cessation
-
2007
- 2007-09-21 CY CY20071101225T patent/CY1106886T1/el unknown
-
2008
- 2008-10-28 JP JP2008277469A patent/JP4423338B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200300145A (et) | Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon | |
| EE200300528A (et) | Cripto valku blokeerivad antikehad ja nende kasutamine | |
| EE200200251A (et) | Uued N-asabitsükloamiidi derivaadid ja nende kasutamine | |
| CY2013032I2 (el) | Συζυγη της εξενδινης-4 και η φαρμακευτικη τους χρηση | |
| DK1417175T3 (da) | Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf | |
| DE60208351D1 (de) | Glukopyranosyloxybenzylbenzolderivate und deren medizinische verwendung | |
| EE05537B1 (et) | Neublastiini polmeerkonjugaadid ja meetodid nende kasutamiseks | |
| EE200200341A (et) | Asendatud oksasolidinoonid ja nende kasutamine | |
| DE50112013D1 (de) | Deodorantien und antiperspirantien | |
| EE200200550A (et) | Karbamaatsed kaspaasi inhibiitorid ja nende kasutamine | |
| AR028622A1 (es) | Derivados de tropano utiles en terapia | |
| EE05475B1 (et) | Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon | |
| DK1284764T3 (da) | Medicinsk apparat | |
| EE200200626A (et) | Antraniilamiidid ja nende kasutamine ravimitena | |
| EE200300311A (et) | Ftalasinoon-piperidinoderivaadid, nende kasutamine ja ravim | |
| FI20010222A0 (fi) | Lääketieteellisesti hammashoidolliset polymeerikomposiitit ja -koostumukset | |
| BRPI0208558A2 (pt) | preparado de combinação de estrogênio-gestagênio e uso | |
| EE200300193A (et) | Asendatud bensimidasoolid, nende kasutamine ja ravim | |
| EE05333B1 (et) | Makroliidhendite konjugaadid p?letikuvastaste henditega ja nende kasutamine | |
| FI20011671A0 (fi) | Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö | |
| FI20000818A0 (fi) | Dermatologinen käyttö ja valmiste | |
| FI20001715A0 (fi) | Rankoihin liittyvät järjestelyt ja menetelmät | |
| EE200300339A (et) | Helicobacter pylory uudsed retseptorid ja nende kasutamine | |
| DE60217539D1 (de) | Leichtathletikschuh | |
| NO20030156D0 (no) | Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC1A | Change of owner name | ||
| MM4A | Lapsed by not paying the annual fees |
Effective date: 20160125 |